Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Postma

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
European Journal of Hospital Pharmacy : Science and Practice|June 4, 2019
Stakeholder opinions on value in healthcareRobert Terkola, Fernando Antoñanzas, Maarten Postma
Pharmacoeconomics|September 29, 2020
Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying TherapiesLuis Hernandez, Malinda O'Donnell, Maarten Postma, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 7, 2017
Economic evaluation of personalized medicine: a call for real-world dataRobert Terkola, Fernando Antoñanzas, Maarten Postma
Pharmacoeconomics|July 23, 2016
The Value of Medicines: A Crucial but Vague ConceptFernando Antoñanzas, Robert Terkola, Maarten Postma
Pharmacoeconomics|July 5, 2018
Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic EvaluationsLuis Hernandez, Malinda O'Donnell, Maarten Postma
The Journal of Infectious Diseases|December 22, 2021
Reply to Anglemyer et alFlorian Zeevat, Cornelis Boersma, Maarten Postma
Frontiers in Pharmacology|October 23, 2012
Stratified medicine and reimbursement issuesHans-Joerg Fugel, Mark Nuijten, Maarten Postma
New Biotechnology|September 25, 2016
Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environmentHans-Joerg Fugel, Mark Nuijten, Maarten Postma
Reproductive Biomedicine Online|December 25, 2009
What's on the mind of IVF consumers?Mark P Connolly, Maarten Postma, Sherman J Silber
Sexually Transmitted Diseases|July 26, 2005
Costs and effects of chlamydial screening: dynamic versus static modelingRobert Welte, Maarten Postma, Reiner Leidl, et al.
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
European Journal of Hospital Pharmacy : Science and Practice|June 4, 2019
Stakeholder opinions on value in healthcareRobert Terkola, Fernando Antoñanzas, Maarten Postma
Pharmacoeconomics|September 29, 2020
Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying TherapiesLuis Hernandez, Malinda O'Donnell, Maarten Postma, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 7, 2017
Economic evaluation of personalized medicine: a call for real-world dataRobert Terkola, Fernando Antoñanzas, Maarten Postma
Pharmacoeconomics|July 23, 2016
The Value of Medicines: A Crucial but Vague ConceptFernando Antoñanzas, Robert Terkola, Maarten Postma
Pharmacoeconomics|July 5, 2018
Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic EvaluationsLuis Hernandez, Malinda O'Donnell, Maarten Postma
The Journal of Infectious Diseases|December 22, 2021
Reply to Anglemyer et alFlorian Zeevat, Cornelis Boersma, Maarten Postma
Frontiers in Pharmacology|October 23, 2012
Stratified medicine and reimbursement issuesHans-Joerg Fugel, Mark Nuijten, Maarten Postma
New Biotechnology|September 25, 2016
Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environmentHans-Joerg Fugel, Mark Nuijten, Maarten Postma
Reproductive Biomedicine Online|December 25, 2009
What's on the mind of IVF consumers?Mark P Connolly, Maarten Postma, Sherman J Silber
Sexually Transmitted Diseases|July 26, 2005
Costs and effects of chlamydial screening: dynamic versus static modelingRobert Welte, Maarten Postma, Reiner Leidl, et al.
Pageof 10